{
  "run_id": "RUN_20260204_234342_996d5a3920e1",
  "timestamp": "2026-02-05T04:24:38.646554",
  "document": "Cerebral-Creatine-Deficiency-Syndromes.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/NLP4RARE/train/Cerebral-Creatine-Deficiency-Syndromes.pdf",
  "pipeline_version": "0.8",
  "total_recommendation_sets": 1,
  "total_recommendations": 1,
  "recommendation_sets": [
    {
      "guideline_name": "Not specified",
      "guideline_year": 2015,
      "organization": "Not specified",
      "target_condition": "Cerebral creatine deficiency syndromes (CCDS)",
      "target_population": null,
      "recommendations": [
        {
          "recommendation_id": "rec_Cerebral-Creatine-Deficiency-Syndromes_1",
          "recommendation_type": "treatment",
          "population": "patients suspected of CCDS",
          "condition": "cerebral creatine deficiency syndromes",
          "severity": "not specified",
          "action": "CCDS screening testing in both urine and plasma",
          "action_description": null,
          "preferred": "measuring concentration of creatine (Cr), guanidinoacetate (GAA), and creatinine (Crn)",
          "alternatives": [],
          "dosing": [],
          "taper_target": "not applicable",
          "duration": "not specified",
          "stop_window": null,
          "evidence_level": "expert_opinion",
          "strength": "strong",
          "references": [],
          "source": "Cerebral-Creatine-Deficiency-Syndromes",
          "source_text": "Testing in both urine and plasma is recommended for all three types of CCDS by measuring the concentration of creatine (Cr), guanidinoacetate (GAA), and creatinine (Crn)",
          "page_num": null
        }
      ],
      "source_document": "Cerebral-Creatine-Deficiency-Syndromes",
      "extraction_confidence": 0.85
    }
  ]
}